A brand new study, authored by KBH Professor Jan Inge Henter and published within the New England Journal of Medicine, has investigated whether or not the drug empagliflozin can scale back the danger of coronary heart failure and loss of life in sufferers who’ve lately suffered a coronary heart assault.
The drug, which is used for sort 2 diabetes and coronary heart failure, was examined on greater than 6,500 sufferers. They had been divided into two teams—one obtained empagliflozin, whereas the opposite was given a placebo (an inactive substance)—and had been adopted for about 18 months.
The outcomes confirmed that though empagliflozin decreased the variety of first hospitalizations for coronary heart failure, it didn’t considerably impression the general danger of coronary heart failure or loss of life in comparison with placebo. This means that the drug might not present the protecting impact towards coronary heart assault that researchers had hoped for.
A constructive facet of the research was that empagliflozin didn’t result in extra unwanted effects than anticipated. Its security profile was according to earlier analysis, which means that the drug was typically nicely tolerated by sufferers.
The study contributes worthwhile data about how SGLT2 inhibitors operate in coronary heart illness and raises new questions on which sufferers might profit most from these drugs. The researchers emphasize that additional research are wanted to grasp the function empagliflozin would possibly play within the therapy of coronary heart assault sufferers sooner or later.
More info:
Jan-Inge Henter et al, Hemophagocytic Lymphohistiocytosis, New England Journal of Medicine (2025). DOI: 10.1056/NEJMra2314005
Citation:
Study yields surprising outcomes from empagliflozin after coronary heart assault (2025, February 20)
21
yields-unexpected-results-empagliflozin-heart.html
.
. The content material is offered for info functions solely.